Elliott Winton MD

Department of Hematology and Medical Oncology
Professor Emeritus

(404) 778-1900
ewinton@emory.edu

Academic Appointment

Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Collaborative Scientist, Emory National Primate Research Center, Emory University School of Medicine

Education

Degrees

MD from University of Chicago School of Medicine
BS from University of Connecticut

Research

Focus

My career long focus has been on clinical and laboratory investigations of normal and malignant hematopoiesis. Specific disease entities for clinical research include acute myeloid leukemia, myelodysplastic, myeloproliferative neoplasms (polycythemia rubra vera, essential thrombocythemia, myelofibrosis) and rare myeloproliferative disorders (systemic mastocytosis, hypereosinophilia).

Publications

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Blood Adv Volume: 8 Page(s): 1515 - 1528
03/26/2024 Authors: Yacoub A; Borate U; Rampal RK; Ali H; Wang ES; Gerds AT; Hobbs G; Kremyanskaya M; Winton E; O'Connell C
MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study.
Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S324
10/01/2022 Authors: Yacoub A; Borate U; Rampal R; Ali H; Wang E; Gerds A; Hobbs G; Kremyanskaya M; Winton E; O'Connell C
A randomized phase 3 trial of interferon- vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood Volume: 139 Page(s): 2931 - 2941
05/12/2022 Authors: Mascarenhas J; Kosiorek HE; Prchal JT; Rambaldi A; Berenzon D; Yacoub A; Harrison CN; McMullin MF; Vannucchi AM; Ewing J
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
Nat Med Volume: 27 Page(s): 2183 - 2191
12/01/2021 Authors: DeAngelo DJ; Radia DH; George TI; Robinson WA; Quiery AT; Drummond MW; Bose P; Hexner EO; Winton EF; Horny H-P
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
JCO Oncol Pract Volume: 17 Page(s): e497 - e505
04/01/2021 Authors: Jillella AP; Arellano ML; Gaddh M; Langston AA; Heffner LT; Winton EF; McLemore ML; Zhang C; Caprara CR; Simon KS
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 697 - 703.e1
10/01/2020 Authors: Coltoff A; Mesa R; Gotlib J; Shulman J; Rampal RK; Siwoski O; Yacoub A; Moliterno A; Yang A; Braunstein E
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
J Clin Med Volume: 9
05/20/2020 Authors: Kong JH; Winton EF; Heffner LT; Gaddh M; Hill B; Neely J; Hatcher A; Joseph M; Arellano M; El-Rassi F
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
J Clin Oncol Volume: 38 Page(s): 1006 - 1018
04/01/2020 Authors: Dao K-HT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
Leukemia Volume: 33 Page(s): 2974 - 2978
12/01/2019 Authors: Mascarenhas J; Kosiorek H; Prchal J; Yacoub A; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Blood Volume: 134 Page(s): 1498 - 1509
10/31/2019 Authors: Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E
TREATMENT OF VENOUS THROMBOEMBOLISM DURING INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
Volume: 93 Page(s): E51 - E51
09/01/2018 Authors: Patel B; Cheng E; McLemore M; Arellano M; Heffner LT; Winton EF; Bodo I; Langston A; Kota V; Gaddh M
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.
Bone Marrow Transplant Volume: 53 Page(s): 826 - 831
07/01/2018 Authors: Khoury HJ; Langston AA; Kota VK; Wilkinson JA; Pusic I; Jillella A; Bauer S; Kim AS; Roberts D; Al-Kadhimi Z
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Lancet Haematol Volume: 5 Page(s): e73 - e81
02/01/2018 Authors: Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J
Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia
Volume: 130
12/07/2017 Authors: Kong JH; Winton EF; Heffner L; Gaddh M; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK
Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)
Volume: 130
12/07/2017 Authors: Kong JH; Winton EF; Heffner L; Gaddh M; Hill B; Arellano ML; El-Rassi F; Kim A; Kota V
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Nave Patients With Myelofibrosis.
J Clin Oncol Volume: 35 Page(s): 3844 - 3850
12/01/2017 Authors: Mesa RA; Kiladjian J-J; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
Clin Lymphoma Myeloma Leuk Volume: 17 Page(s): e71 - e73
12/01/2017 Authors: Kota VK; Kong JH; Arellano M; El Rassi F; Gaddh M; Heffner LT; Winton EF; Jillella AP; McLemore ML; Khoury HJ
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Cancer Volume: 123 Page(s): 2482 - 2488
07/01/2017 Authors: Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Lancet Haematol Volume: 4 Page(s): e317 - e324
07/01/2017 Authors: Harrison CN; Schaap N; Vannucchi AM; Kiladjian J-J; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC
PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY
Volume: 102 Page(s): 320 - 320
06/26/2017 Authors: Gotlib JR; Kiladjian J-J; Catalano JV; Devos T; Egyed M; Hellman A; McLornan DP; Shimoda K; Winton EF; Deng W
PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
Volume: 102 Page(s): 320 - 321
06/26/2017 Authors: Verstovsek S; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
J Hematol Oncol Volume: 10 Page(s): 55
02/22/2017 Authors: Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MWN; Miller CB; Silver RT; Talpaz M
Clinical Value of Targeted Panel Next-Generation Sequencing in BCR-ABL1-Negative Myeloproliferative Neoplasms
Volume: 97 Page(s): 387A - 387A
02/01/2017 Authors: Yang T; Box A; Winton E; Hill CE; Zhang L
Clinical Value of Targeted Panel Next-Generation Sequencing in BCR-ABL1-Negative Myeloproliferative Neoplasms
Volume: 30 Page(s): 387A - 387A
02/01/2017 Authors: Yang T; Box A; Winton E; Hill CE; Zhang L
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Future Oncol Volume: 13 Page(s): 395 - 407
02/01/2017 Authors: Winton EF; Kota V
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Haematologica Volume: 102 Page(s): 327 - 335
02/01/2017 Authors: Mascarenhas JO; Talpaz M; Gupta V; Foltz LM; Savona MR; Paquette R; Turner AR; Coughlin P; Winton E; Burn TC
Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions
Volume: 128
12/02/2016 Authors: Kong JH; Khoury HJ; Winton EF; Heffner LT; Gaddh M; Arellano M; El-Rassi F; Kim AS; Jillella A; Bodo I
DECREASING EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN AN ACADEMIC CENTER IN THE US BY USING A SIMPLIFIED TREATMENT ALGORITHM AND DEDICATED APL EXPERTS
Volume: 101 Page(s): 675 - 676
06/01/2016 Authors: Jillella A; Mody M; Harpaul G; Arellano M; Khoury H; Al-Kadhimi Z; McLemore M; Winton E; Gaddh M; Heffner L
Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.
Volume: 34
05/20/2016 Authors: Gupta V; Verstovsek S; Mesa RA; Gotlib JR; DiPersio JF; Catalano JV; Deininger MWN; Miller CB; Silver RT; Talpaz M
Costs associated with induction chemotherapy in adult acute myeloid leukemia (AML) managed in a tertiary care specialized unit.
Volume: 34
05/20/2016 Authors: Gleason S; Howard DH; Liu Y; Goldstein DA; Arellano ML; Jillella AP; Gaddh M; Kota V; Winton EF; Heffner LT
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience
Volume: 126
12/03/2015 Authors: Khoury HJ; Heffner LT; Arellano M; Jillella AP; Kota VK; Winton EF
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors
Volume: 126
12/03/2015 Authors: Kota VK; Winton EF; Arellano M; Jillella A; McLemore ML; El Rassi F; Khoury HJ
Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)
Volume: 126
12/03/2015 Authors: Khoury HJ; Kota V; Arellano M; Bauer SL; Jillella AP; Langston A; Al-Kadhimi Z; DeFilipp Z; Kim AS; Winton EF
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 514 - 518
09/01/2015 Authors: Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A
Ruxolitinib for the treatment of patients with polycythemia vera.
Expert Rev Hematol Volume: 8 Page(s): 391 - 401
08/01/2015 Authors: Kiladjian J-J; Winton EF; Talpaz M; Verstovsek S
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Haematologica Volume: 100 Page(s): 479 - 488
04/01/2015 Authors: Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MWN; Miller CB; Silver RT
Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?
Cancer Volume: 121 Page(s): 872 - 875
03/15/2015 Authors: El Rassi F; Bergsagel JD; Arellano M; Gaddh M; Jillella A; Kota V; Heffner LT; Winton EF; Khoury HJ
Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis
BLOOD Volume: 124
12/06/2014 Authors: Mascarenhas JO; Talpaz M; Gupta V; Foltz LM; Savona MR; Paquette R; Turner R; Coughlin P; Winton E; Hunter D
Early Blast Phase Transformation In Chronic Phase Chronic Myeloid Leukemia: Is Flow Cytometry The Missing Link?
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S136 - S137
09/01/2014 Authors: El Rassi F; Arellano M; Winton E; Heffner L; Gaddh M; Khoury HJ
Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
South Med J Volume: 107 Page(s): 497 - 500
08/01/2014 Authors: El Rassi F; Ward KC; Flowers CR; Heffner LT; Waller EK; Winton EF; Vaughn J; Hill BG; Langston A; Nooka A
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma.
Leuk Lymphoma Volume: 55 Page(s): 1498 - 1500
07/01/2014 Authors: Mitri Z; Siddiqui MT; El Rassi F; Holden JT; Heffner LT; Langston A; Waller EK; Winton E; McLemore M; Bernal-Mizrachi L
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
Haematologica Volume: 99 Page(s): 292 - 298
02/01/2014 Authors: Mesa RA; Kiladjian J-J; Verstovsek S; Al-Ali HK; Gotlib J; Gisslinger H; Levy R; Siulnik A; Gupta V; Khan M
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
Leuk Res Rep Volume: 3 Page(s): 67 - 69
01/01/2014 Authors: Dao K-HT; Solti MB; Maxson JE; Winton EF; Press RD; Druker BJ; Tyner JW
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Haematologica Volume: 98 Page(s): 1865 - 1871
12/01/2013 Authors: Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MWN; Miller CB; Silver RT
Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
Cancer Volume: 119 Page(s): 3784 - 3787
11/01/2013 Authors: Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
J Hematol Oncol Volume: 6 Page(s): 81
10/29/2013 Authors: Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Br J Haematol Volume: 161 Page(s): 508 - 516
05/01/2013 Authors: Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
J Clin Oncol Volume: 31 Page(s): 1285 - 1292
04/01/2013 Authors: Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF
Incidence and Geographic Distribution of Adult Acute Lymphoblastic Leukemia in the State of Georgia
Volume: 120
11/16/2012 Authors: El Rassi F; Arellano M; Heffner LT; Waller EK; Winton EF; Ward K; Khoury HJ
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
Cancer Volume: 118 Page(s): 5278 - 5282
11/01/2012 Authors: Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.
Br J Haematol Volume: 158 Page(s): 608 - 614
09/01/2012 Authors: Muringampurath-John D; Jaye DL; Flowers CR; Saxe D; Chen Z; Lechowicz MJ; Weisenburger DD; Bast M; Arellano ML; Bernal-Mizrachi L
Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50-100x10(9)/L
Volume: 30
05/20/2012 Authors: Talpaz M; Hamburg SI; Jamieson K; Terebelo HR; Afrin L; Winton EF; Scola MA; Lyons RM; Harvey JH; Holmes CE
Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.
Volume: 30
05/20/2012 Authors: Verstovsek S; Mesa RA; Gotlib JR; Gupta V; DiPersio JF; Catalano JV; Deininger MWN; Miller CB; Silver RT; Talpaz M
Managing chronic myeloid leukemia: a coordinated team care perspective.
Clin Lymphoma Myeloma Leuk Volume: 12 Page(s): 88 - 93
04/01/2012 Authors: Holloway S; Lord K; Bethelmie-Bryan B; Shepard MW; Neely J; McLemore M; Reddy SK; Montero A; Jonas WS; Gladney SP
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
Leuk Lymphoma Volume: 53 Page(s): 725 - 727
04/01/2012 Authors: Muringampurath-John D; Flowers CR; Toscano M; Zhengjia C; Kaufman JL; Arellano M; Bernal-Mizrachi L; Heffner LT; Lechowicz M-J; McLemore M
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N Engl J Med Volume: 366 Page(s): 799 - 807
03/01/2012 Authors: Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years.
Cancer Volume: 118 Page(s): 428 - 433
01/15/2012 Authors: Arellano M; Winton E; Pan L; Lima L; Tighiouart M; Bhalla K; Heffner LT; Neely J; Hutcherson D; McLemore M
Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF
Volume: 118 Page(s): 1642 - 1643
11/18/2011 Authors: Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano J; Deininger MW; Shields A; Miller CB; Silver RT; Talpaz M
Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I
Volume: 118 Page(s): 128 - 129
11/18/2011 Authors: Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano J; Deininger MW; Miller CB; Silver RT
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 427 - 432
10/01/2011 Authors: Arellano M; Bernal-Mizrachi L; Pan L; Tighiouart M; Souza L; Guo X; McLemore M; Lima L; Sunay S; Heffner LT
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
Leuk Lymphoma Volume: 52 Page(s): 1010 - 1016
06/01/2011 Authors: Lima LM; Sampat K; Assouline S; Saxe D; Nault S; Tighiouart M; McLemore M; Arellano M; Winton E; Bernal-Mizrachi L
Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
Cancer Volume: 117 Page(s): 1245 - 1252
03/15/2011 Authors: Lima L; Bernal-Mizrachi L; Saxe D; Mann KP; Tighiouart M; Arellano M; Heffner L; McLemore M; Langston A; Winton E
Long-term treatment with rituximab of autoimmune autonomic ganglionopathy in a patient with lymphoma.
Arch Neurol Volume: 68 Page(s): 372 - 375
03/01/2011 Authors: Hollenbeck R; Black BK; Peltier AC; Biaggioni I; Robertson D; Winton EF; Raj SR
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Clin Cancer Res Volume: 17 Page(s): 1140 - 1146
03/01/2011 Authors: Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S
Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters.
Leuk Lymphoma Volume: 51 Page(s): 1473 - 1477
08/01/2010 Authors: Tran H; Arellano M; Chamsuddin A; Flowers C; Heffner LT; Langston A; Lechowicz MJ; Tindol A; Waller E; Winton EF
Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
Clin Lymphoma Myeloma Leuk Volume: 10 Page(s): 285 - 289
08/01/2010 Authors: Parikh SA; Kantarjian H; Schimmer A; Walsh W; Asatiani E; El-Shami K; Winton E; Verstovsek S
Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Arellano ML; Pan L; Lima L; Tighiouart M; Heffner LT; Langston AA; McLemore M; Neely J; Winton EF; Khoury HJ
Spectrum of FDG PET/CT findings in Burkitt lymphoma.
Clin Nucl Med Volume: 34 Page(s): 355 - 358
06/01/2009 Authors: Zeng W; Lechowicz MJ; Winton E; Cho S-M; Galt JR; Halkar R
Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
J Clin Oncol Volume: 27 Page(s): 7064
05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).
J Clin Oncol Volume: 27 Page(s): 7070
05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ
Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
Volume: 27
05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML)
Volume: 27
05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ
Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)?
J Clin Oncol Volume: 27 Page(s): 7071
05/20/2009 Authors: Lima L; Assouline SE; Saxe D; Mann K; McLemore M; Souza L; Arellano M; Winton EF; Bernal-Mizrachi L; Khoury HJ
Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)?
Volume: 27
05/20/2009 Authors: Lima L; Assouline SE; Saxe D; Mann K; McLemore M; Souza L; Arellano M; Winton EF; Bernal-Mizrachi L; Khoury HJ
Acquired copper deficiency: a potentially serious and preventable complication following gastric bypass surgery.
Obesity (Silver Spring) Volume: 17 Page(s): 827 - 831
04/01/2009 Authors: Griffith DP; Liff DA; Ziegler TR; Esper GJ; Winton EF
A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.
Volume: 112 Page(s): 679 - 679
11/16/2008 Authors: Lancet JE; Winton EF; Stuart RK; Burton M; Cubitt C; Blaskovich M; Wright J; Sebti S; Sullivan D
Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
Volume: 112 Page(s): 1247 - 1247
11/16/2008 Authors: Langston AA; Murali S; McMillan S; Heffner LT; Lonial S; Waller EK; Flowers CR; Kaufman J; McLemore ML; Sinha R
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
Bone Marrow Transplant Volume: 42 Page(s): 529 - 534
10/01/2008 Authors: Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP
Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Biol Blood Marrow Transplant Volume: 13 Page(s): 116 - 123
01/01/2007 Authors: Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Deep venous thromboses associated with peripherally inserted central catheters in patients with hematological malignancies.
Volume: 108 Page(s): 226B - 226B
11/16/2006 Authors: Tran H; Chamsuddin A; Winton EF; Heffner L; Langston A; Waller N; Arellano M; Khoury HJ
Benefits of CHOP-14 followed by transplantation in patients with peripheral T-cell lymphoma.
Volume: 108 Page(s): 254B - 254B
11/16/2006 Authors: Abouyabis AN; Lechowicz M; Mann K; Heffner LT; Winton E; Bucur S; Flowers CR
Tolerability and anti-leukemic activity of ara-C, topotecan, and gemtuzumab ozogamicin [ATGO] in advanced MDS and AML: Interim analysis of phase I/II data.
Volume: 108 Page(s): 554A - 554A
11/16/2006 Authors: Murali S; Winton EF; McMillan S; Lonial S; Waller N; Heffner L; Flowers C; Kaufman JL; Lechowicz MJ; Khoury HJ
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Leuk Lymphoma Volume: 47 Page(s): 2155 - 2162
10/01/2006 Authors: Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
Reduced-intensity conditioning permits a significant graft vs leukemia (GvL) effect for acute leukemia
Volume: 12 Page(s): 69 - 70
02/01/2006 Authors: Arellano M; Flowers C; Waller E; Lonial S; Kaufman J; Winton E; Khoury H; Langston A
Patient characteristics in CD 20(+) and CD 20(-) adult acute lymphoblastic leukemia (ALL): A single institution analysis.
Volume: 106 Page(s): 210B - 210B
11/16/2005 Authors: Gladney SP; Heffner LT; Langston A; Holden J; Phillips C; Winton E; Flowers CR; Lechowicz MJ; Lonial S; Waller E
Decreased incidence of relapse in patients with acute leukemia transplanted from matched unrelated donors: Induction of GvL
Volume: 106 Page(s): 570A - 571A
11/16/2005 Authors: Arellano ML; Langston A; Lonial S; Flowers C; Khoury JH; Winton E; Waller EK; Mary LJ
High resolution amplicon melting curve analysis: A sensitive and rapid method to detect the janus kinase 2 (JAK2) gene mutation.
Volume: 106 Page(s): 323B - 323B
11/16/2005 Authors: Park SI; Winton EF; Mann KP; Hill CE
Relapse free survival of elderly AML patients is comparable to that of younger adults when treated with a modified dose intensive cytarabine regimen.
Volume: 106 Page(s): 237B - 237B
11/16/2005 Authors: Langston AA; Heffner LT; Hutcherson D; Neely J; Flowers C; Waller EK; Lonial S; Khoury HJ; Winton E
Prognostic significance of early peripheral blood blasts clearance following induction chemotherapy for adult acute myeloid leukemia.
Volume: 106 Page(s): 236B - 236B
11/16/2005 Authors: Pakkala S; Winton E; Langston A; Heffner LT; Khoury HJ
Results of a clinical phase I dose-escalation study of cylarabine in combination with fixed dose vinorelbine, paclitaxel, etoposide, and cisplatin (VTEPA) for the treatment of relapsed/refractory lymphoma.
Volume: 23 Page(s): 607S - 607S
06/01/2005 Authors: Arellano ML; Lonial S; Langston A; Flowers C; Heffner T; Hutcherson D; Winton E; Waller E
A phase I trial of ara-C, topotecan, and gemtuzumab ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
Volume: 104 Page(s): 502A - 502A
11/16/2004 Authors: Langston AA; McMillan S; Lonial S; Smith K; Waller EK; Heffner LT; Bucur S; Redei I; Flowers C; Lechowicz MJ
Update in acute leukemia 2003: A risk adapted approach to acute myeloblastic leukemia in adults
Volume: 31 Page(s): 80 - 86
04/01/2004 Authors: Winton EF; Langston AA
Update on myelodysplastic syndromes: New approaches to classification and therapy
Volume: 31 Page(s): 72 - 79
04/01/2004 Authors: Langston AA; Walling R; Winton EF
Update in acute leukemia 2003: a risk adapted approach to acute myeloblastic leukemia in adults.
Semin Oncol Volume: 31 Page(s): 80 - 86
04/01/2004 Authors: Winton EF; Langston AA
Update on myelodysplastic syndromes: new approaches to classification and therapy.
Semin Oncol Volume: 31 Page(s): 72 - 79
04/01/2004 Authors: Langston AA; Walling R; Winton EF
A phase I study of dose escalated cytarabine in combination with a modified ESHAP-like regimen, paclitaxel, and vinorelbine (VTEPA) for the treatment of relapsed/refractory lymphoma.
Volume: 102 Page(s): 293B - 293B
11/16/2003 Authors: Lonial S; Tanner A; Langston AA; Redei I; Heffner LT; Bucur SZ; Hutcherson D; Winton E; Waller EK
Early autologous transplantation for mantle cell lymphoma may improve long term disease-free survival.
Volume: 102 Page(s): 734A - 735A
11/16/2003 Authors: Murali S; Lonial S; Redei I; Smith K; Waller EK; Heffner LT; Bucur S; Winton E; Manion K; Langston A
A phase I trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
Volume: 102 Page(s): 333B - 333B
11/16/2003 Authors: Langston AA; Tanner A; Lonial S; Heffner LT; Smith K; Bucur S; Waller EK; Redei I; Winton E
Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma.
Volume: 100 Page(s): 178A - 178A
11/16/2002 Authors: Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S
Non-fatal Veno-Occlusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin).
BLOOD Volume: 98 Page(s): 201B - 202B
11/16/2001 Authors: Langston AA; Feinstein B; Hutcherson D; Heffner LT; Redei I; Smith K; Lonial S; Bucur S; Jones A; Waller EK
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Blood Volume: 96 Page(s): 2246 - 2253
09/15/2000 Authors: Fang G; Kim CN; Perkins CL; Ramadevi N; Winton E; Wittmann S; Bhalla KN
Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells.
Leukemia Volume: 14 Page(s): 412 - 418
03/01/2000 Authors: Boyer MW; Waller EK; Bray RA; Unangst T; Johnson TS; Phillips C; Jurickova I; Winton EF; Yeager AM
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.
Leuk Lymphoma Volume: 36 Page(s): 497 - 502
02/01/2000 Authors: Lonial S; Jones TW; Devine S; Winton EF; Heffner LT; Smith KJ; Yeager AM; Waller EK
Modified high dose Ara-C (mHiDAC) and daunorubicin as induction therapy for newly diagnosed AML without t(15;17).
BLOOD Volume: 94 Page(s): 233B - 233B
11/15/1999 Authors: Lonial S; Langston AA; Bhalla K; Smith KJ; Heffner LT; Bucur S; Hutcherson DA; Winton EF
Autologous peripheral blood stem cell (PBSC) transplantation in AML: Outcome and flow cytometric analysis of the PBSC product.
BLOOD Volume: 94 Page(s): 398B - 398B
11/15/1999 Authors: Bucur SZ; Heffner LT; Langston AA; Redei J; Waller EK; Winton EF; Holden JT; Smith KJ
Purpura Fulminans and S. pneumoniae sepsis with severe acquired protein C deficiency successfully treated with recombinant human activated protein C
THROMBOSIS AND HAEMOSTASIS Page(s): 738 - 738
08/01/1999 Authors: Smith KJ; Neal J; Winton EF; LaRosa S; Fisher CJ
Bone marrow response to exogenously administered cytokines in a cohort of rhesus macaques infected with monocytotropic strain, SIVmac239 17E.
BLOOD Volume: 92 Page(s): 380A - 381A
11/15/1998 Authors: Bucur SZ; Gillespie TW; Lee ME; Adams JW; Bray RA; Villinger F; Winton EF; Novembre F; Ansari A; Hillyer CD
Hematopoietic reserve and mobilization potential, and viral load during early and late stage SIV.
BLOOD Volume: 92 Page(s): 381A - 381A
11/15/1998 Authors: Bucur SZ; Gillespie TW; Lee ME; Adams JW; Bray RA; Villinger F; Winton EF; Novembre F; Ansari AA; Hillyer DC
Hematologic and virologic effects of lineage-specific and non-lineage-specific recombinant human and rhesus cytokines in a cohort of SIVmac239-infected macaques.
AIDS Res Hum Retroviruses Volume: 14 Page(s): 651 - 660
05/20/1998 Authors: Bucur SZ; Lackey DA; Adams JW; Lee ME; Villinger F; Mayne A; Bray RA; Winton EF; Novembre F; Strobert EA
The number of CD34+, CD38- cells in the graft predicts the kinetics of hematopoietic reconstitution following autologous or allogeneic bone marrow transplantation (BMT).
BLOOD Volume: 90 Page(s): 1753 - 1753
11/15/1997 Authors: Waller EK; Lynn M; Worford L; Winton EF; Redei I; Heffner T; Hillyer CD; Smith K; Bucur S; Lopez R
Ectopic expression of p185 Bcr-Abl in human AML HL-60 cells blocks myeloid but allows erythroid differentiation and growth inhibition due to low-dose Ara-C or ATRA.
BLOOD Volume: 90 Page(s): 3998 - 3998
11/15/1997 Authors: Huang Y; Kim CN; Holden J; AmaranteMendes GP; Winton EF; Perkins CL; Green DR; Bhalla K
7.5 Gy irradiation attenuates the graft-vs host disease (GvHD) potential of allogeneic lymphocytes while preserving anti-leukemic activity in pre-clinical and clinical studies.
BLOOD Volume: 90 Page(s): 2437 - 2437
11/15/1997 Authors: Waller EK; Redei I; Yeager AM; Winton EF; Heffner T; Hillyer CD; Carter R; Smith K; Holland HK; Connaghan G
Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
Bone Marrow Transplant Volume: 20 Page(s): 219 - 225
08/01/1997 Authors: Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I
Platelet recovery following autologous bone marrow transplantation correlates with the content of CD34+, CD38-cells in the marrow graft.
EXPERIMENTAL HEMATOLOGY Volume: 25 Page(s): 598 - 598
08/01/1997 Authors: Waller EK; Worford LJ; Lynn M; Winton EF; Bray RA; Jones W; Rosenthal H; McCollum J; Holland HK; Yeager AM
Presence of minimal residual disease (MRD) in acute myelogenous leukemia (AML) patients preallogeneic bone marrow transplantation (BMT) is associated with a lower relapse-free survival (RFS).
EXPERIMENTAL HEMATOLOGY Volume: 25 Page(s): 621 - 621
08/01/1997 Authors: Holland HK; Bray RA; OToole K; Holden JT; Connaghan DG; Heffner LT; Waller EK; Winton EF; Yeager AM
The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Biol Blood Marrow Transplant Volume: 3 Page(s): 25 - 33
04/01/1997 Authors: Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT
Recombinant human (rh) FLT3 ligand plus rhGM-CSF or rhG-CSF causes a marked CD34+ cell mobilization to blood in rhesus monkeys
BLOOD Volume: 88 Page(s): 2556 - 2556
11/15/1996 Authors: Winton EF; Bucur SZ; Bond LD; Hegwood AJ; Hillyer CD; Holland NK; Williams DE; McClure HM; Troutt AB; Lyman SD
Studies of the effects of recombinant human (RH) and rhesus (RH) cytokines on hematologic and virologic parameters in a cohort SIVmac239 infected macaques.
BLOOD Volume: 88 Page(s): 1376 - 1376
11/15/1996 Authors: Hillyer CD; Lackey DA; Bucur SZ; Adams JW; Lee ME; Buccolo LS; Trainor LD; Villinger F; Mayne A; Bray RA
Vancomycin-resistant Aureobacterium species cellulitis and bacteremia in a patient with acute myelogenous leukemia.
J Clin Microbiol Volume: 34 Page(s): 1992 - 1994
08/01/1996 Authors: Nolte FS; Arnold KE; Sweat H; Winton EF; Funke G
Long term follow-up of edelfosine purging for autologous bone marrow transplantation (ABMT) in acute leukemia.
EXPERIMENTAL HEMATOLOGY Volume: 24 Page(s): 615 - 615
08/01/1996 Authors: Vogler WR; Berdel WE; Winton EF; Gordon DS; Geller RB; Heffner LT; Brochstein JA; Beveridge RA; Dalton WS; Miller KB
Profile of cell cycle in hematopoietic malignancy by DNA/RNA quantitation using 7AAD/PY.
Exp Hematol Volume: 24 Page(s): 894 - 901
07/01/1996 Authors: Toba K; Kishi K; Koike T; Winton EF; Takahashi H; Nagai K; Maruyama S; Furukawa T; Hashimoto S; Masuko M
Reverse transcriptase-polymerase chain reaction for bcr/abl fusion in chronic myelogenous leukemia.
Am J Clin Pathol Volume: 105 Page(s): 756 - 760
06/01/1996 Authors: Wells SJ; Phillips CN; Winton EF; Farhi DC
Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
J Clin Oncol Volume: 14 Page(s): 1156 - 1164
04/01/1996 Authors: Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR
Association of busulfan area under the curve with veno-occlusive disease following BMT.
Bone Marrow Transplant Volume: 17 Page(s): 225 - 230
02/01/1996 Authors: Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB
A nonhuman primate model for the study of effects of cytokines on hematopoietic reconstitution following chemotherapy-induced marrow damage
Volume: 94 Page(s): 75 - 81
01/01/1996 Authors: Winton EF; Hillyer CD; Srinivasiah J; Kim BK; Strobert EA; Orkin JL; Swenson RB; McClure HM; Myers LA
High dose cyclophosphamide, fractionated total body irradiation with involved field irradiation and autologous bone marrow transplantation in malignant lymphoma.
Leuk Lymphoma Volume: 20 Page(s): 249 - 257
01/01/1996 Authors: Tirona MR; Gordon DS; Crocker I; Eley JW; York R; Heffner LT; Winton EF; Vogler WR
Treatment of chronic neutropenia associated with large granular lymphocytosis with cyclosporine A and filgrastim.
Am J Hematol Volume: 50 Page(s): 288 - 291
12/01/1995 Authors: Jakubowski A; Winton EF; Gencarelli A; Gabrilove J
Studies of the pharmacokinetics and toxicity of once daily bolus intravenous busulfan in non-human primates.
BLOOD Volume: 86 Page(s): 888 - 888
11/15/1995 Authors: Dix SP; Bucur SZ; Mullins RE; McCulloch W; Thomas GR; Hillyer CD; McClure HM; Strobert EA; Orkin JL; Winton EF
Risk factors for severe acute renal failure (ARF) after matched unrelated donor transplantation (MUDT).
BLOOD Volume: 86 Page(s): 1552 - 1552
11/15/1995 Authors: Redei S; Geller RB; Devine S; OToole K; Persons L; Holland HK; Connaghan G; Fleming WH; Heffner LT; Hillyer C
Phase I trial of busulfan (BU), cyclophosphamide (CY), and diaziquone (AZQ) following autologous (AU) or allogeneic (AL) bone marrow transplantation (BMT).
BLOOD Volume: 86 Page(s): 831 - 831
11/15/1995 Authors: Devine SM; Dix SP; Geller RB; Holland HK; Colbaugh J; Connaghan DG; Fleming WH; Hillyer CD; Mullins R; Waller EK
The hematopoietic effects of recombinant human (rh) FLT3 ligand administered to non-human primates.
BLOOD Volume: 86 Page(s): 1681 - 1681
11/15/1995 Authors: Winton EF; Bucur SZ; Bray RA; Toba K; Williams DE; McClure HM; Lyman SD
Transplantation of HLA-identical positively selected CD34+ cells of peripheral blood (PBSC) and marrow (BM) from related donors results in prompt engraftment and low incidence of GVHD in recipients undergoing allogeneic transplantation
BLOOD Volume: 86 Page(s): 1543 - 1543
11/15/1995 Authors: Holland HK; Bray AM; Geller RB; Devine SM; McCollum J; Connaghan DG; Fleming WH; Heffner LT; Hillyer C; Waller EK
Tacrolimus (FK506) combined with methotrexate (MTX) is effective in preventing acute graft versus host disease (AGVHD) following related donor allogeneic bone marrow transplantation (BMT).
BLOOD Volume: 86 Page(s): 1569 - 1569
11/15/1995 Authors: Devine SM; Geller RB; Dix SP; Connaghan DG; Fleming WH; Heffner LT; Hillyer CD; Holland HK; Waller EK; Winton EF
Evaluation of supportive care guidelines for monitoring breast cancer bone marrow transplant (BMT) patients in the outpatient setting.
BLOOD Volume: 86 Page(s): 838 - 838
11/15/1995 Authors: Miyahara TT; Dix SP; Devine SM; Holland HK; Connaghan DG; Fleming WH; Geller RB; Heffner LT; Hillyer CD; Waller EK
Total CD34+ cell content and CFU-GEMM are not good predictors of time to neutrophil engraftment following matched unrelated donor (MUD) transplantation.
BLOOD Volume: 86 Page(s): 467 - 467
11/15/1995 Authors: Holland HK; Geller RB; Redei S; Bray R; Winton EF; Connaghan DG; OToole K; Person L; Devine SM; Wingard JR
Synthokine effect on the hematopoietic system and the effect of synthokine priming on subsequent hepsulfam-induced marrow injury using a non-human primate model
BLOOD Volume: 86 Page(s): 2741 - 2741
11/15/1995 Authors: Bucur SZ; Strobert EA; Hillyer CD; Orkin JL; McClure HM; McKearn JP; Winton EF
Antiproliferative effect of human interleukin-4 in human cancer cell lines: studies on the mechanism.
Leuk Lymphoma Volume: 19 Page(s): 319 - 328
10/01/1995 Authors: Topp MS; Papadimitriou CA; Eitelbach F; Oelmann E; Koehler B; Oberberg D; Von Marschall Z; Reufi B; Stein H; Thiel E
PREDICTION OF A THRESHOLD AND OPTIMALLY EFFECTIVE THROMBOCYTOPOIETIC DOSE OF RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN NONHUMAN-PRIMATES BASED ON MURINE PHARMACOKINETIC DATA
EXPERIMENTAL HEMATOLOGY Volume: 23 Page(s): 879 - 879
08/01/1995 Authors: WINTON EF; THOMAS GR; MARIAN ML; BUCUR SZ; MCCLURE HM; EATON DL
Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino-actinomycin D and pyronin Y.
J Immunol Methods Volume: 182 Page(s): 193 - 207
06/09/1995 Authors: Toba K; Winton EF; Koike T; Shibata A
Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer.
Bone Marrow Transplant Volume: 15 Page(s): 935 - 942
06/01/1995 Authors: Lazarus HM; Winton EF; Williams SF; Grinblatt D; Campion M; Cooper BW; Gunn H; Manfreda S; Isaacs RE
Chemotherapy-induced hemolytic uremic syndrome: description of a potential animal model.
J Med Primatol Volume: 24 Page(s): 68 - 73
02/01/1995 Authors: Hillyer CD; Duncan A; Ledford M; Barrett TJ; Klumpp SA; Anderson DC; McClure HM; Winton EF
INTENSIVE TIME-SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONE AND ARA-C FOR PATIENTS (PTS) WITH NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) OR REFRACTORY RELAPSE ACUTE-LEUKEMIA - A POTENTIAL ROLE FOR GM-CSF TO ENHANCE RECRUITMENT
BLOOD Volume: 84 Page(s): A144 - A144
11/15/1994 Authors: GELLER RB; MORRIS L; WINTON EF; BRAY R; HEFFNER LT; HOLLAND KH; GILMORE C; DEVINE S; FARHI D; JAMISON K
SIMULTANEOUS ADMINISTRATION OF INTERLEUKEN-6 (RHIL-6) AND NEUPOGEN(R) (RHG-CSF) FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FOR BREAST-CANCER (BCA)
BLOOD Volume: 84 Page(s): A89 - A89
11/15/1994 Authors: DEVINE SM; WINTON EF; HOLLAND HK; GELLER RB; HEFFNER LT; HILLYER CD; MORRIS LE; RODEY GE; BEVERIDGE R; LYNCH J
FK506-BASED IMMUNOSUPPRESSION FOR PREVENTION OF GRAFT-VERSUS-HOST-DISEASE (GVHD) AFTER MATCHED UNRELATED DONOR (MUD) MARROW TRANSPLANTATION
BLOOD Volume: 84 Page(s): A341 - A341
11/15/1994 Authors: DEVINE SM; GELLER RB; HOLLAND HK; MORRIS LE; WINTON EF; HEFFNER LT; HILLYER CD; RODEY GE; DIX SP; OTOOLE K
BONE-MARROW TRANSPLANTATION (BMT) FOR INDOLENT LYMPHOMA UTILIZING BUSULFAN (BU), CYCLOPHOSPHAMIDE (CY) AND ETOPOSIDE (E) FOLLOWED BY MAINTENANCE ALPHA-INTERFERON (IF) - 2-YEAR FOLLOW-UP RESULTS
BLOOD Volume: 84 Page(s): A209 - A209
11/15/1994 Authors: HOLLAND HK; HEFFNER LT; GELLER RB; DEVINE SM; HILLYER CD; WINTON EF; SARAL R; WINGARD JR
Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model.
Blood Volume: 84 Page(s): 65 - 73
07/01/1994 Authors: Winton EF; Srinivasiah J; Kim BK; Hillyer CD; Strobert EA; Orkin JL; Swenson RB; McClure HM; Myers LA; Saral R
T-cell receptor gene rearrangement in T-cell large granular leukocyte leukemia: preferential V alpha but diverse J alpha usage in one of five patients.
Blood Volume: 83 Page(s): 767 - 775
02/01/1994 Authors: Kasten-Sports C; Zaknoen S; Steis RG; Chan WC; Winton EF; Waldmann TA
Different mechanisms of inhibition by alkyl-lysophospholipid and phorbol ester of granulocyte-macrophage colony-stimulating factor binding to human leukemic cell lines.
Exp Hematol Volume: 22 Page(s): 13 - 18
01/01/1994 Authors: Shoji M; Fukuhara T; Winton EF; Berdel WE; Vogler WR
HIGH-DOSE BUSULFAN (BU), VP-16, CYTOXAN (CY) WITH MARROW RESCUE (BMT) FOR MULTIPLE-MYELOMA (MM)
BLOOD Volume: 82 Page(s): A578 - A578
11/15/1993 Authors: SEAY TE; DEVINE SM; GELLER RT; HEFFNER LT; HILLYER C; HOLLAND HK; RODEY GE; SARAL R; VOGLER WR; WINTON EF
INTENSIVE TIMED SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONE AND ARA-C FOR ADULT PATIENTS WITH ACUTE-LEUKEMIA
BLOOD Volume: 82 Page(s): A538 - A538
11/15/1993 Authors: GELLER RB; SIDHU GK; BRAY K; GILMORE C; KLEIN L; ROTHFIELD C; HEFFNER LT; HOLLAND HK; SEAY TE; WINTON EF
ASSOCIATION OF BUSULFAN AREA-UNDER-THE-CURVE (AUC) WITH VENOOCCLUSIVE DISEASE (VOD) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT)
BLOOD Volume: 82 Page(s): A418 - A418
11/15/1993 Authors: DIX SP; MULLINS RE; JERKUNICA I; DAVIDSON TG; GILMORE CE; YORK RC; LIN LS; DEVINE SM; GELLER RB; HEFFNER LT
PHASE-1 STUDY OF RECOMBINANT HUMAN INTERLEUKIN-6 (RHIL-6, ESCHERICHIA-COLI) AFTER AUTOLOGOUS BONE-MARROW TRANSPLANT (ABMT) IN PATIENTS WITH POOR-PROGNOSIS BREAST-CANCER
BLOOD Volume: 82 Page(s): A173 - A173
11/15/1993 Authors: LAZARUS HM; WINTON EF; WILLIAMS SF; GRINBLATT D; CAMPION M; MANFREDA S; COOPER BW; ISAACS RE
THE EFFECT OF VARYING RATIOS OF ADMINISTERED RHIL-3 AND RHGM-CSF ON POSTCHEMOTHERAPY MARROW REGENERATION IN A NONHUMAN PRIMATE MODEL
BLOOD Volume: 82 Page(s): A365 - A365
11/15/1993 Authors: GONTER PW; HILLYER CD; STROBERT EA; ORKIN JL; SWENSON RB; MCCLURE HM; MYERS LA; WINTON EF
ENHANCED POSTCHEMOTHERAPY PLATELET AND NEUTROPHIL RECOVERY USING COMBINATION RHIL-6 AND RHGM-CSF OR RHG-CSF IN A NONHUMAN PRIMATE MODEL
BLOOD Volume: 82 Page(s): A365 - A365
11/15/1993 Authors: GONTER PW; HILLYER CD; STROBERT EA; ORKIN JL; SWENSON RB; MCCLURE HM; MYERS LA; WINTON EF
Effects of recombinant human granulocyte-macrophage colony-stimulating factor on platelet survival and activation using a nonhuman primate model.
Exp Hematol Volume: 21 Page(s): 1577 - 1582
11/01/1993 Authors: Tomer A; Stahl CP; McClure HM; Anderson DC; Myers LA; Liehl E; Winton EF
Peripheral blood stem cell acquisition by large-volume leukapheresis in growth factor-stimulated and unstimulated rhesus monkeys: development of an animal model.
Exp Hematol Volume: 21 Page(s): 1455 - 1459
10/01/1993 Authors: Hillyer CD; Swenson RB; Hart KK; Lackey DA; Winton EF
CD34+ and CFU-GM progenitors are significantly decreased in SIVsmm9 infected rhesus macaques with minimal evidence of direct viral infection by polymerase chain reaction.
Am J Hematol Volume: 43 Page(s): 274 - 278
08/01/1993 Authors: Hillyer CD; Lackey DA; Villinger F; Winton EF; McClure HM; Ansari AA
CHEMOTHERAPY-INDUCED HEMOLYTIC-UREMIC SYNDROME - DESCRIPTION OF A POTENTIAL ANIMAL-MODEL
THROMBOSIS AND HAEMOSTASIS Volume: 69 Page(s): 1027 - 1027
06/30/1993 Authors: HILLYER CD; DUNCAN A; LEDFORD M; BARRETT TJ; KLUMPP SA; ANDERSON DC; MCCLURE HM; WINTON EF
A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.
Blood Volume: 81 Page(s): 2496 - 2502
05/15/1993 Authors: Dale DC; Bonilla MA; Davis MW; Nakanishi AM; Hammond WP; Kurtzberg J; Wang W; Jakubowski A; Winton E; Lalezari P
Differential effects of sequential, simultaneous, and single agent interleukin-3 and granulocyte-macrophage colony-stimulating factor on megakaryocyte maturation and platelet response in primates.
Blood Volume: 80 Page(s): 2479 - 2485
11/15/1992 Authors: Stahl CP; Winton EF; Monroe MC; Haff E; Holman RC; Myers L; Liehl E; Evatt BL
The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
Br J Haematol Volume: 82 Page(s): 337 - 346
10/01/1992 Authors: Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
Phase II clinical trial of carboplatin in relapsed and refractory leukemia.
Leukemia Volume: 6 Page(s): 1072 - 1075
10/01/1992 Authors: Vogler WR; Harrington DP; Winton EF; Lazarus HM; Bennett JM; Cassileth PA; Oken MM
Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid.
Blood Volume: 80 Page(s): 1423 - 1429
09/15/1992 Authors: Vogler WR; Berdel WE; Olson AC; Winton EF; Heffner LT; Gordon DS
Granulocyte colony-stimulating factor: a new approach in the treatment of childhood neutropenia.
J Med Assoc Ga Volume: 81 Page(s): 437 - 441
08/01/1992 Authors: Little FM; Pais RC; Winton E; Ragab AH
Risk factors for cytomegalovirus pneumonia following allogeneic bone marrow transplantation after prophylaxis with intravenous immunoglobulin.
Volume: 29 Page(s): 89 - 95
07/01/1992 Authors: Krischer J; Elfenbein G; Babington R; Hong R; Jansen J; Lazarus H; Winton E; Rand K
Studies of an improved rhesus hematopoietic progenitor cell assay.
Exp Hematol Volume: 20 Page(s): 401 - 404
05/01/1992 Authors: Winton EF; Jacobs PC; Rozmiarek SK; Stahl CP; Myers LA; Liehl E; Stoll RE; Anderson DC; McClure HM
Improved staining method for the simultaneous flow cytofluorometric analysis of DNA content, S-phase fraction, and surface phenotype using single laser instrumentation.
Cytometry Volume: 13 Page(s): 60 - 67
01/01/1992 Authors: Toba K; Winton EF; Bray RA
Effects of human interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates.
Blood Volume: 78 Page(s): 1467 - 1475
09/15/1991 Authors: Stahl CP; Zucker-Franklin D; Evatt BL; Winton EF
Recombinant human granulocyte-macrophage colony-stimulating factor promotes megakaryocyte maturation in nonhuman primates.
Exp Hematol Volume: 19 Page(s): 810 - 816
09/01/1991 Authors: Stahl CP; Winton EF; Monroe MC; Holman RC; Zelasky M; Liehl E; Myers LA; McClure H; Anderson D; Evatt BL
INVIVO EFFECT OF INTERLEUKIN-6 ON MEGAKARYOCYTE (MK) DEVELOPMENT
CLINICAL RESEARCH Volume: 39 Page(s): A269 - A269
04/01/1991 Authors: STAHL CP; ZUCKERFRANKLIN D; EVATT BL; WINTON EF
Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation.
Bone Marrow Transplant Volume: 6 Page(s): 405 - 409
12/01/1990 Authors: Vogler WR; Winton EF; Heffner LT; Gordon DS; Sternberg P; Crocker I; Reynolds R; Dobbs CK
The ontogeny of a 57-Kd cationic antimicrobial protein of human polymorphonuclear leukocytes: localization to a novel granule population.
Blood Volume: 76 Page(s): 825 - 834
08/15/1990 Authors: Pereira HA; Spitznagel JK; Winton EF; Shafer WM; Martin LE; Guzman GS; Pohl J; Scott RW; Marra MN; Kinkade JM
Modulation of retinoic acid-induced differentiation of human leukemia (HL-60) cells by serum factors and sphinganine.
Cancer Res Volume: 50 Page(s): 222 - 226
01/15/1990 Authors: Stevens VL; Owens NE; Winton EF; Kinkade JM; Merrill AH
Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Leuk Res Volume: 14 Page(s): 895 - 903
01/01/1990 Authors: Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
Granulocyte/macrophage colony-stimulating factor primes human neutrophils for increased diacylglycerol generation in response to chemoattractant.
FEBS Lett Volume: 257 Page(s): 188 - 190
10/23/1989 Authors: Tyagi SR; Winton EF; Lambeth JD
Preclinical studies on deoxycoformycin and deoxyadenosine as pharmacologic T cell purging tools.
Bone Marrow Transplant Volume: 4 Page(s): 511 - 517
09/01/1989 Authors: Sheridan W; Gordon DS; Fullen AJ; Olson A; Vogler WR; Winton E
Differential effects of long-chain (sphingoid) bases on the monocytic differentiation of human leukemia (HL-60) cells induced by phorbol esters, 1 alpha, 25-dihydroxyvitamin D3, or ganglioside GM3.
Cancer Res Volume: 49 Page(s): 3229 - 3234
06/15/1989 Authors: Stevens VL; Winton EF; Smith EE; Owens NE; Kinkade JM; Merrill AH
Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice.
Exp Hematol Volume: 17 Page(s): 364 - 367
05/01/1989 Authors: Berdel WE; Okamoto S; Danhauser-Riedl S; Hong CI; Winton EF; West CR; Rastetter J; Vogler WR
Factors affecting survival in allogeneic bone marrow transplantation.
Am J Med Sci Volume: 297 Page(s): 300 - 308
05/01/1989 Authors: Vogler WR; Winton EF; Reynolds RC; Heffner LT; Gordon DS
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
Cancer Volume: 63 Page(s): 1055 - 1059
03/15/1989 Authors: Lazarus HM; Vogler WR; Burns CP; Winton EF
Interim results of a multicenter trial to prevent cytomegalovirus pneumonia after allogeneic bone marrow transplantation.
Transplant Proc Volume: 21 Page(s): 3099 - 3100
02/01/1989 Authors: Elfenbein G; Krischer J; Babington R; Hong R; Jansen J; Lazarus H; Winton E; Rand K
Various human hematopoietic growth factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells.
Blood Volume: 73 Page(s): 80 - 83
01/01/1989 Authors: Berdel WE; Danhauser-Riedl S; Steinhauser G; Winton EF
Leukemia of non-T lineage natural killer cells.
Blood Volume: 72 Page(s): 1701 - 1707
11/01/1988 Authors: Sheridan W; Winton EF; Chan WC; Gordon DS; Vogler WR; Phillips C; Bongiovanni KF; Waldmann TA
Transient bone marrow aplasia associated with non-A, non-B hepatitis.
Am J Hematol Volume: 29 Page(s): 168 - 171
11/01/1988 Authors: Dhingra K; Michels SD; Winton EF; Gordon DS
RECOMBINANT HUMAN GM-CSF AND IL-3 STIMULATE CLONOGENICITY OF HUMAN-TUMOR CELL-LINES INVITRO
BLUT Volume: 57 Page(s): 178 - 178
10/01/1988 Authors: BERDEL WE; DANHAUSER S; WINTON EF
RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR STIMULATES CLONOGENICITY OF A HUMAN-COLON TUMOR-CELL LINE INVITRO
EXPERIMENTAL HEMATOLOGY Volume: 16 Page(s): 510 - 510
07/01/1988 Authors: BERDEL WE; DANHAUSER S; WINTON EF
INTERLEUKIN-1 STIMULATION OF HEMATOPOIETIC GROWTH-FACTOR PRODUCTION BY HUMAN-BONE MARROW FIBROBLASTS
EXPERIMENTAL HEMATOLOGY Volume: 16 Page(s): 504 - 504
07/01/1988 Authors: BROOKBANK KGM; WOODLEY MA; WINTON EF
FACTORS AFFECTING SURVIVAL IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
EXPERIMENTAL HEMATOLOGY Volume: 16 Page(s): 495 - 495
07/01/1988 Authors: VOGLER WR; WINTON EF; HEFFNER LT; GORDON DS; REYNOLDS RC
PROTEIN KINASE-C INVOLVEMENT IN HL-60 DIFFERENTIATION PROBED BY LONG-CHAIN (SPHINGOID) BASES
FASEB JOURNAL Volume: 2 Page(s): A1622 - A1622
03/25/1988 Authors: STEVENS VL; OWENS N; WINTON EF; KINKADE JM; MERRILL AH
Large granular lymphocyte proliferation: an analysis of T-cell receptor gene arrangement and expression and the effect of in vitro culture with inducing agents.
Blood Volume: 71 Page(s): 52 - 58
01/01/1988 Authors: Chan WC; Dahl C; Waldmann T; Link S; Mawle A; Nicholson J; Bach FH; Bongiovanni K; McCue PA; Winton EF
Preliminary results of a multicenter trial to prevent death from cytomegalovirus pneumonia with intravenous immunoglobulin after allogeneic bone marrow transplantation.
Transplant Proc Volume: 19 Page(s): 138 - 143
12/01/1987 Authors: Elfenbein G; Krischer J; Rand K; Graham-Pole J; Jansen J; Winton E; Hong R; Lazarus H; Babington R
The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.
Proc Natl Acad Sci U S A Volume: 84 Page(s): 5394 - 5398
08/01/1987 Authors: Tsudo M; Goldman CK; Bongiovanni KF; Chan WC; Winton EF; Yagita M; Grimm EA; Waldmann TA
Use of long-term human marrow cultures to demonstrate progenitor cell precursors in marrow treated with 4-hydroperoxycyclophosphamide.
Exp Hematol Volume: 15 Page(s): 710 - 714
07/01/1987 Authors: Winton EF; Colenda KW
CLINICAL-FEATURES IN LARGE ANTIGRANULOCYTES LYMPHOCYTIC-LEUKEMIA
BLOOD Volume: 69 Page(s): 1786 - 1786
06/01/1987 Authors: CHAN WC; WINTON EF
Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid.
Blood Volume: 69 Page(s): 1381 - 1387
05/01/1987 Authors: Okamoto S; Olson AC; Vogler WR; Winton EF
THE SENSITIVITY OF LEUKEMIC PROGENITORS TO THE CYTOTOXIC EFFECT OF ETHER LIPIDS
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 28 Page(s): 208 - 208
03/01/1987 Authors: OKAMOTO S; OLSON AC; WINTON EF; VOGLER WR
A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients.
Cancer Invest Volume: 5 Page(s): 267 - 273
01/01/1987 Authors: Vogler WR; Malcom LG; Winton EF
TYPE-B LARGE ANTIGRANULOCYTES LYMPHOCYTE-PROLIFERATION - A CLINICAL, IMMUNOLOGICAL AND T-CELL RECEPTOR GENE ARRANGEMENT STUDY
LABORATORY INVESTIGATION Volume: 56 Page(s): A12 - A12
01/01/1987 Authors: CHAN WC; LINK S; WALDMANN TA; MAWLE A; CHECK IJ; WINTON EF
Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes.
Blood Volume: 68 Page(s): 1142 - 1153
11/01/1986 Authors: Chan WC; Link S; Mawle A; Check I; Brynes RK; Winton EF
High incidence of veno-occlusive disease related to indicine N-oxide in the treatment of refractory adult acute leukemia.
Cancer Treat Rep Volume: 70 Page(s): 933 - 934
07/01/1986 Authors: Winton EF; McCue PA
Lymphocytosis of large granular lymphocytes.
Arch Intern Med Volume: 146 Page(s): 1201 - 1203
06/01/1986 Authors: Chan WC; Winton EF; Waldmann TA
LYMPHOCYTOSIS OF LARGE ANTIGRANULOCYTES LYMPHOCYTES
ARCHIVES OF INTERNAL MEDICINE Volume: 146 Page(s): 1201 - 1203
06/01/1986 Authors: CHAN WC; WINTON EF; WALDMANN TA
Spontaneous regression of a monoclonal proliferation of large granular lymphocytes associated with reversal of anemia and neutropenia.
Blood Volume: 67 Page(s): 1427 - 1432
05/01/1986 Authors: Winton EF; Chan WC; Check I; Colenda KW; Bongiovanni KF; Waldmann TA
Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
Cancer Treat Rep Volume: 70 Page(s): 455 - 459
04/01/1986 Authors: Vogler WR; Preisler HD; Winton EF; Gottlieb AJ; Goldberg J; Brennan J; Grunwald H; Rai K; Browman G; Miller KB
HETEROGENEITY OF LARGE ANTIGRANULOCYTES LYMPHOCYTES - DELINEATION OF SUBSETS WITH DISTINCT ORIGIN, IMMUNOPHENOTYPE AND FUNCTIONAL-CHARACTERISTICS
FEDERATION PROCEEDINGS Volume: 45 Page(s): 1101 - 1101
03/05/1986 Authors: CHAN WC; DAHL C; MAWLE A; LINK S; NICHOLSON J; WINTON EF; MCCUE P; BACH FH
THE EFFECT OF CRYOPRESERVATION ON ALKYL-LYSOPHOSPHOLIPID (ALP) TREATED HUMAN STEM-CELLS AND LEUKEMIC-CELLS (HL-60)
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 27 Page(s): 193 - 193
03/01/1986 Authors: OKAMOTO S; OLSON A; WINTON EF; VOGLER WR
Antigen detection in immune complexes by a modified staphylococci binding assay and Western blot analysis.
Clin Immunol Immunopathol Volume: 38 Page(s): 184 - 197
02/01/1986 Authors: McDougal JS; Kennedy MS; Hubbard M; Browning SW; Tsang VC; Winton EF; McDuffie FC
HETEROGENEITY OF LARGE ANTIGRANULOCYTES LYMPHOCYTE PROLIFERATIONS
LABORATORY INVESTIGATION Volume: 54 Page(s): A11 - A11
01/01/1986 Authors: CHAN WC; LINK S; MAWLE A; CHECK IC; BRYNES RK; WINTON EF
Studies on the use of nonhuman primates to determine the DR status of the human hematopoietic stem cell.
Exp Hematol Volume: 13 Page(s): 869 - 873
10/01/1985 Authors: Winton EF; Colenda KW; McClure HM; Chan WC; Gordon DS
Treatment of patients with acute nonlymphocytic leukemia in relapse: a Leukemia Intergroup study.
Am J Hematol Volume: 19 Page(s): 167 - 176
06/01/1985 Authors: Goldberg J; Grunwald H; Vogler WR; Winton E; Browman G; Walker I; Benger A; Miller KB; Rai K; Gottlieb AJ
USE OF LONG-TERM HUMAN MARROW CULTURES TO DEMONSTRATE PROGENITOR-CELL PRECURSORS IN 4-HYDROPEROXYCYCLOPHOSPHAMIDE (4-HC) TREATED MARROW
EXPERIMENTAL HEMATOLOGY Volume: 13 Page(s): 343 - 343
01/01/1985 Authors: WINTON EF; COLENDA KW
Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
Cancer Treat Rep Volume: 69 Page(s): 807 - 811
01/01/1985 Authors: Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
Br J Haematol Volume: 58 Page(s): 19 - 32
09/01/1984 Authors: Preisler HD; Epstein J; Barcos M; Priore R; Raza A; Browman GP; Vogler R; Winton E; Grunwald H; Rai K
The effect of alkyl-lysophospholipids on tritiated thymidine incorporation and clonogenicity in vitro of normal and leukemic human cells.
Exp Hematol Volume: 12 Page(s): 569 - 574
08/01/1984 Authors: Vogler WR; Whigham EA; Somberg LB; Long RC; Winton EF
Clostridium difficile. Colonization and toxin production in a cohort of patients with malignant hematologic disorders.
Arch Intern Med Volume: 144 Page(s): 967 - 969
05/01/1984 Authors: Morris JG; Jarvis WR; Nunez-Montiel OL; Towns ML; Thompson FS; Dowell VR; Hill EO; Vogler WR; Winton EF; Hughes JM
A morphologic and immunologic study of the large granular lymphocyte in neutropenia with T lymphocytosis.
Blood Volume: 63 Page(s): 1133 - 1140
05/01/1984 Authors: Chan WC; Check I; Schick C; Brynes RK; Kateley J; Winton EF
A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
Blood Volume: 63 Page(s): 1039 - 1045
05/01/1984 Authors: Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
Transferrin in disease. I: A potential prognostic indicator in patients undergoing bone marrow transplantation.
Am J Clin Pathol Volume: 81 Page(s): 581 - 585
05/01/1984 Authors: Hunter RL; Bennett B; Garrison C; Winton EF; Vogler WR
T-cell imbalance in neutropenia of uncertain etiology.
Am J Clin Pathol Volume: 81 Page(s): 54 - 61
01/01/1984 Authors: Chan WC; Winton EF; Check IJ
A COMPARISON OF THE PATTERN OF EXPRESSION OF IA-ANTIGEN RECOGNIZED BY MURINE ANTIHUMAN IA MONOCLONAL-ANTIBODY (MCAB) ON HEMATOPOIETIC PROGENITORS FROM HIGHER PRIMATES AND MAN
EXPERIMENTAL HEMATOLOGY Volume: 12 Page(s): 423 - 423
01/01/1984 Authors: WINTON EF; COLENDA KW; MCCLURE HM; GORDON DS
Autologous marrow transplantation after karyotypic conversion to normal in blastic phase of chronic myelocytic leukemia.
Am J Med Volume: 75 Page(s): 1080 - 1084
12/01/1983 Authors: Vogler WR; Winton EF; James S; O'Neill S; Granade S; Mallard G
False-positive counterimmunoelectrophoresis tests for Clostridium difficile: the role of Clostridium bifermentans and Clostridium sordellii.
J Infect Dis Volume: 148 Page(s): 1168 - 1169
12/01/1983 Authors: Jarvis W; Nunez-Monteil O; Thompson F; Dowell V; Towns M; Morris G; Vogler W; Winton E; Hill E
Phase II study of amsacrine gluconate in refractory leukemia.
Cancer Treat Rep Volume: 67 Page(s): 1131 - 1132
12/01/1983 Authors: Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ
The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemia.
Am J Hematol Volume: 15 Page(s): 227 - 235
11/01/1983 Authors: Browman G; Goldberg J; Gottlieb AJ; Preisler HD; Azarnia N; Priore RL; Brennan JK; Vogler WR; Winton EF; Miller KB
Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
Cancer Treat Rep Volume: 67 Page(s): 977 - 980
11/01/1983 Authors: Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M
Dose in granulocyte transfusion.
Ann Intern Med Volume: 98 Page(s): 257
02/01/1983 Authors: Winton EF; Vogler WR; Glasser L
LYMPHOCYTOSIS OF LARGE GRANULAR LYMPHOCYTES IN NEUTROPENIA - A CLINICAL MORPHOLOGIC, AND IMMUNOLOGICAL STUDY
LABORATORY INVESTIGATION Volume: 48 Page(s): A13 - A14
01/01/1983 Authors: CHAN WC; CHECK IJ; SCHICK C; BRYNES RK; WINTON EF
Acute tumor lysis in T-cell leukemia induced by amsacrine.
Arch Intern Med Volume: 143 Page(s): 165 - 166
01/01/1983 Authors: Vogler WR; Morris JG; Winton EF
Dosage and scheduling regimens for glucocorticoids.
J Clin Apher Volume: 1 Page(s): 144 - 148
01/01/1983 Authors: Winton EF; Vogler WR; Mishler JM
CLOSTRIDIUM-BIFERMENTANS IN A COHORT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES
CLINICAL RESEARCH Volume: 31 Page(s): A366 - A366
01/01/1983 Authors: JARVIS W; NUNEZMONTIEL O; TOWNS M; THOMPSON F; MORRIS J; DOWELL V; HILL E; VOGLER W; WINTON E; HUGHES J
PHASE-II STUDY OF AMSACRINE (M-AMSA) GLUCONATE IN REFRACTORY ADULT ACUTE-LEUKEMIA
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 23 Page(s): 112 - 112
01/01/1982 Authors: OMURA GA; WINTON EF; VOGLER WR; ZUCKERMAN KS; GRILLOLOPEZ AJ
THE EFFECT OF ALKYL-LYSOPHOSPHOLIPID (ET18-OCH3) ON GRANULOCYTE-MACROPHAGE PROGENITOR CELLS FROM NORMAL AND CHRONIC MYELOCYTIC LEUKEMIC MARROWS
EXPERIMENTAL HEMATOLOGY Volume: 10 Page(s): 15 - 15
01/01/1982 Authors: VOGLER WR; WINTON EF; BOGGS R; LONG R; TIDWELL T; BARASHICK L; LAVIA D
Autologous marrow transplantation: current status and future directions.
Prog Clin Cancer Volume: 8 Page(s): 45 - 56
01/01/1982 Authors: Vogler WR; Winton EF
Influence of quantity of granulocytes transfused on response.
Prog Clin Biol Res Volume: 88 Page(s): 75 - 91
01/01/1982 Authors: Winton EF; Moffitt S; Vogler WR; Mallard HE; Lawson DH; Malcom LG; Montagne ML
Temporal correlation of the marrow's production of granulopoietic stimulatory activity and granulocyte regeneration after vinblastine.
Exp Hematol Volume: 9 Page(s): 619 - 627
07/01/1981 Authors: Winton EF; Vogler WR; Parker MB; Kinkade JM
Chromatographic isolation of two murine leukocyte peroxidases distinct from eosinophil peroxidase: isoenzymes or cell line-specific proteins?
J Reticuloendothel Soc Volume: 29 Page(s): 451 - 458
06/01/1981 Authors: Pember SO; Kellar KL; Winton EF; Kinkade JM
In vitro studies of lactoferrin and murine granulopoiesis.
Blood Volume: 57 Page(s): 574 - 578
03/01/1981 Authors: Winton EF; Kinkade JM; Vogler WR; Parker MB; Barnes KC
Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine, and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia.
Cancer Treat Rep Volume: 65 Page(s): 389 - 392
01/01/1981 Authors: Winton EF; Miller D; Vogler WR
PROGNOSTIC FACTORS AFFECTING REMISSION INDUCTION AND DURATION IN ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 22 Page(s): 489 - 489
01/01/1981 Authors: VOGLER WR; WINTON EF; GORDON DS; JARRELL R; LEFANTE J
Collection and transfusion of granulocytes from stimulated donors.
Prog Clin Biol Res Volume: 65 Page(s): 29 - 40
01/01/1981 Authors: Vogler WR; Lawson DH; Moffitt S; Mallard HE; Winton EF
QUALITATIVE CHANGES IN MYELOPEROXIDASE ACTIVITY IN DENSITY-GRADIENT FRACTIONATED PERITONEAL-EXUDATE CELLS
FEDERATION PROCEEDINGS Volume: 39 Page(s): 1748 - 1748
01/01/1980 Authors: PEMBER SO; WINTON EF; KINKADE JM
PHASE-II STUDY OF ACRIDINYL ANISIDIDE (M-AMSA)(NSC-249992) IN REFRACTORY ADULT ACUTE-LEUKEMIA
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 21 Page(s): 437 - 437
01/01/1980 Authors: WINTON EF; VOGLER WR; ROSE KL
Immunochemical quantificaion of in vitro neutrophilic granulocyte differentiation.
Nature Volume: 277 Page(s): 225 - 227
01/18/1979 Authors: Kinkade JM; Kellar KL; Winton EF
INTENSIVE CHEMOTHERAPY FOR THE ACCELERATED PHASE OF CHRONIC GRANULOCYTIC-LEUKEMIA (AP-CGL)
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 20 Page(s): 370 - 370
01/01/1979 Authors: WINTON EF; MILLER D; VOGLER WR
Colony stimulating activity and continuous flow centrifugation leukapheresis induced proteinuria.
Exp Hematol Volume: 7 Page(s): 27 - 35
01/01/1979 Authors: Vogler WR; Winton EF; Guzman G
Development of a practical oral dexamethasone premedication schedule leading to improved granulocyte yields with the continuous-flow centrifugal blood cell separator.
Blood Volume: 52 Page(s): 249 - 253
07/01/1978 Authors: Winton EF; Vogler WR
QUANTITATION OF NEUTROPHILIC GRANULOCYTE (NG) DIFFERENTIATION INVITRO - EFFECT OF INCREASING CONCENTRATION AND WITHDRAWAL OF COLONY STIMULATING ACTIVITY (CSA)
JOURNAL OF SUPRAMOLECULAR STRUCTURE Page(s): 172 - 172
01/01/1978 Authors: WINTON EF; VOGLER WR; KELLAR KL; PARKER MB; BARNES KC; KINKADE JM
METHODS OF COLLECTION AND RESULTS OF TRANSFUSION OF GRANULOCYTES
EXPERIMENTAL HEMATOLOGY Volume: 6 Page(s): 93 - 93
01/01/1978 Authors: VOGLER WR; WINTON EF; LAWSON DH
PHASE-1 STUDY OF 5FU - METHYL CCNU - METHOTREXATE WITH LEUCOVORIN IN ADVANCED ADENOCARCINOMA
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 19 Page(s): 326 - 326
01/01/1978 Authors: NIXON DW; VOGLER WR; JACOBS J; HEFFNER LT; WINTON EF; GARRETT PR
GRANULOCYTE-SPECIFIC PROTEIN-SYNTHESIS IN LIQUID CULTURES OF MURINE BONE-MARROW STIMULATED BY COLONYSTIMULATING ACTIVITY
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 19 Page(s): 181 - 181
01/01/1978 Authors: KELLAR KL; WINTON EF; KINKADE JM
QUANTITATION OF NEUTROPHILIC GRANULOCYTE (NG) DIFFERENTIATION INVITRO USING A COMBINATION OF RADIOIMMUNOASSAY AND IMMUNOCYTOFLUORESCENCE METHODS
FEDERATION PROCEEDINGS Volume: 37 Page(s): 1698 - 1698
01/01/1978 Authors: KELLAR KL; BARNES KC; WINTON EF; KINKADE JM
TIME RELATED FLUCTUATIONS OF COLONY STIMULATING ACTIVITY PRODUCTION BY MARROW CELLS AND REAPPEARANCE OF GRANULOPOIETIC CELLS FOLLOWING VINBLASTINE CHEMOTHERAPY
EXPERIMENTAL HEMATOLOGY Volume: 6 Page(s): 78 - 78
01/01/1978 Authors: WINTON EF; VOGLER WR; PARKER MB; KINKADE JM
A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia.
Am J Med Volume: 63 Page(s): 548 - 555
10/01/1977 Authors: Vogler WR; Winton EF
Slide chamber culture system for the in vitro study of humoral regulation of granulocyte and monocyte-macrophage proliferation and differentiation.
Blood Volume: 50 Page(s): 289 - 302
08/01/1977 Authors: Winton EF; Vogler WR; Kellar KL; Parker MB; Kinkade JM
EFFECTS OF VARYING CONCENTRATIONS OF COLONY STIMULATING ACTIVITY (CSA) ON RATES OF INVITRO PROLIFERATION AND DIFFERENTIATION OF MURINE GRANULOCYTES
BLOOD Volume: 50 Page(s): 165 - 165
01/01/1977 Authors: WINTON EF; VOGLER WR; KELLAR KL; KINKADE JM
COLONY STIMULATING ACTIVITY (CSA)-DEPENDENT SYNTHESIS OF GRANULOCYTE SPECIFIC PROTEINS IN LIQUID CULTURES OF MURINE BONE-MARROW
BLOOD Volume: 50 Page(s): 151 - 151
01/01/1977 Authors: KELLAR KL; WINTON EF; KINKADE JM
EVIDENCE THAT MURINE GRANULOCYTES AND MONOCYTES-MACROPHAGES CONTAIN BIOCHEMICALLY DIFFERENT MYELOPEROXIDASES
BLOOD Volume: 50 Page(s): 151 - 151
01/01/1977 Authors: KINKADE JM; PEMBER SO; KELLAR KL; WINTON EF
New trends in the management of adult acute leukemia.
J Med Assoc Ga Volume: 65 Page(s): 380 - 382
10/01/1976 Authors: Vogler WR; Winton EF
Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.
Cancer Treat Rep Volume: 60 Page(s): 895 - 901
07/01/1976 Authors: Vogel CL; Winton EF; Moore MR; Sohner S
EFFICACY OF GRANULOCYTE TRANSFUSIONS (GT) IN NEUTROPENIC PATIENTS
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 17 Page(s): 252 - 252
01/01/1976 Authors: VOGLER WR; WINTON EF
Humoral granulopoietic inhibitors: a review.
Exp Hematol Volume: 3 Page(s): 337 - 353
11/01/1975 Authors: Vogler WR; Winton EF
Hemoglobin Atlanta or alpha 2 beta 2 75 Leu-Pro (E19): an unstable variant found in several members of a Caucasian family.
Biochim Biophys Acta Volume: 386 Page(s): 538 - 541
04/29/1975 Authors: Hubbard M; Winton EF; Lindeman JG; Dessauer PL; Wilson JB; Wrightstone RN; Huisman TH